Dr. Reddy's Laboratories Ltd (RDY)
NYSE:RDY
Want to see RDY full AI Analyst Report?
Total Valuation
Dr Reddy's Laboratories has a market cap or net worth of $11.62B. The enterprise value is $1.17T.
Market Cap$11.62B
Enterprise Value$1.17T
Share Statistics
Dr Reddy's Laboratories has 834,617,900 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding834,617,900
Owned by Insiders―
Owned by Institutions3.50%
Financial Efficiency
Dr Reddy's Laboratories’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is 8.10%.
Return on Equity (ROE)0.12
Return on Assets (ROA)0.08
Return on Invested Capital (ROIC)8.10%
Return on Capital Employed (ROCE)0.12
Revenue Per Employee13.07M
Profits Per Employee1.67M
Employee Count27,048
Asset Turnover0.62
Inventory Turnover2.23
Valuation Ratios
The current PE Ratio of Dr Reddy's Laboratories is 23.9. Dr Reddy's Laboratories’s PEG ratio is -1.16.
PE Ratio23.9
PS Ratio3.05
PB Ratio2.91
Price to Fair Value2.91
Price to FCF33.56
Price to Operating Cash Flow20.14
PEG Ratio-1.16
Income Statement
In the last 12 months, Dr Reddy's Laboratories had revenue of 353.47B and earned 45.09B in profits. Earnings per share was 53.92.
Revenue353.47B
Gross Profit186.52B
Operating Income48.87B
Pretax Income57.68B
Net Income45.09B
EBITDA70.55B
Earnings Per Share (EPS)53.92
Cash Flow
In the last 12 months, operating cash flow was 56.55B and capital expenditures -32.29B, giving a free cash flow of 24.26B billion.
Operating Cash Flow56.55B
Free Cash Flow24.26B
Free Cash Flow per Share29.06
Dividends & Yields
Dr Reddy's Laboratories pays an annual dividend of $0.091, resulting in a dividend yield of 0.64%
Dividend Per Share$0.091
Dividend Yield0.64%
Payout Ratio11.24%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.45
52-Week Price Change-5.41%
50-Day Moving Average13.94
200-Day Moving Average14.05
Relative Strength Index (RSI)45.30
Average Volume (3m)2.26M
Important Dates
Dr Reddy's Laboratories upcoming earnings date is Jul 29, 2026, Before Open (Confirmed).
Last Earnings DateMay 12, 2026
Next Earnings DateJul 29, 2026
Ex-Dividend Date―
Financial Position
Dr Reddy's Laboratories as a current ratio of 1.80, with Debt / Equity ratio of 20.51%
Current Ratio1.80
Quick Ratio1.35
Debt to Market Cap0.07
Net Debt to EBITDA0.86
Interest Coverage Ratio12.42
Taxes
In the past 12 months, Dr Reddy's Laboratories has paid 13.00B in taxes.
Income Tax13.00B
Effective Tax Rate0.23
Enterprise Valuation
Dr Reddy's Laboratories EV to EBITDA ratio is 16.13, with an EV/FCF ratio of 35.45.
EV to Sales3.22
EV to EBITDA16.13
EV to Free Cash Flow35.45
EV to Operating Cash Flow20.09
Balance Sheet
Dr Reddy's Laboratories has $86.08B in cash and marketable securities with $75.81B in debt, giving a net cash position of $10.27B billion.
Cash & Marketable Securities$86.08B
Total Debt$75.81B
Net Cash$10.27B
Net Cash Per Share$12.30
Tangible Book Value Per Share$309.11
Margins
Gross margin is 52.77%, with operating margin of 13.83%, and net profit margin of 12.76%.
Gross Margin52.77%
Operating Margin13.83%
Pretax Margin16.32%
Net Profit Margin12.76%
EBITDA Margin19.96%
EBIT Margin13.83%
Analyst Forecast
The average price target for Dr Reddy's Laboratories is ―, which is 11.43% higher than the current price. The consensus rating is Moderate Sell
Price Target―
Price Target Upside―
Analyst ConsensusModerate Sell
Analyst Count1
Revenue Growth Forecast-1.13%
EPS Growth Forecast-26.68%